The U.S. Food and Drug Administration (FDA) approved a supplemental efficacy application for Enhertu (fam-trastuzumab deruxtecan-nxki) on April 5, 2024. This approval, sponsored by Daiichi Sankyo, indicates an expansion of the drug's approved uses based on new efficacy data, building upon its existing indications.
Background
Enhertu (fam-trastuzumab deruxtecan-nxki) is a prescription medication. The sponsor for Enhertu is Daiichi Sankyo. Supplemental applications like this one are submitted to the FDA to request approval for changes to an already approved drug, such as a new indication, a new patient population, or a new dosing regimen, based on demonstrated efficacy from clinical studies. This particular approval specifically relates to the drug's efficacy profile.
What this means
This supplemental efficacy approval for Enhertu signifies that the FDA has reviewed new clinical data demonstrating the drug's effectiveness for an expanded indication or patient population. This decision provides clinicians with a broader range of approved uses for Trastuzumab Deruxtecan, which may lead to updated treatment guidelines and improved outcomes for additional patient groups who could benefit from its therapeutic effects. The specific details of the expanded indication or population are outlined in the official FDA approval documents associated with this supplemental application, identified as BLA 761139 S-28.
Source
The information regarding this supplemental approval was obtained from the U.S. Food and Drug Administration (FDA) official database. The approval for BLA 761139 S-28, pertaining to Enhertu (fam-trastuzumab deruxtecan-nxki), was dated April 5, 2024, and is publicly accessible on the accessdata.fda.gov website.